SynthesisFrontiers in oncology2023
Clinical utility of the pan-immune-inflammation value in breast cancer patients.
Synthesis in Frontiers in oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Predicting the prognosis of breast cancer patients by using pan-immune-inflammation value: a systematic review and meta-analysis.Scientific reports · 2025Pooled it
- First-Line Palbociclib/Letrozole Versus Ribociclib/Letrozole in Postmenopausal HR-Positive/HER2-Negative Metastatic Breast Cancer: A Retrospective Real-World Study and an Exploratory Composite Clinical-Inflammatory Risk Score.Medicina (Kaunas, Lithuania) · 2026Article
- CALLY index as an independent predictor of pathological complete response in HER2-positive breast cancer receiving neoadjuvant therapy.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Article
- Pan-immune-inflammation value as a predictor of loss of ambulation in duchenne muscular dystrophy: a retrospective cohort study.BMC pediatrics · 2026Article
- Prognostic significance of the pan-immune-inflammatory value (PIV) in gastric cancer: a retrospective cohort study.BMC cancer · 2026Article
- Pan-immune-inflammation value predicts 2-year recurrence after chemoradiotherapy in nasopharyngeal carcinoma.Frontiers in medicine · 2026Article
- Prognostic significance of pan-immune-inflammatory value in adverse cardiovascular and cerebrovascular events post-percutaneous coronary intervention in diabetic patients with coronary heart disease.Frontiers in cardiovascular medicine · 2026Article
- Clinical and pathological indicators for predicting disease-free survival after radical surgery in elderly patients with early-stage triple-negative invasive ductal carcinoma of the breast.Frontiers in oncology · 2026Article
- Pan-Immune-Inflammatory Value as a Systemic Inflammation Marker Associated with Cardiovascular-Kidney-Metabolic Syndrome: Evidence from a Cross-Sectional Study of 751 Patients.Cardiorenal medicine · 2026Observational
- Pan-immune-inflammation value: racial variations and differences in prognostic accuracy across breast cancer subtypes at a single institution.Frontiers in oncology · 2026Article
- Pan-Immune-Inflammatory value and risk of latent tuberculosis infection.Scientific reports · 2025Article
- Pan-Immune-Inflammation Value as a Predictor of Long-Term Outcomes in Patients with Urothelial Carcinoma of the Bladder: A Pilot Study.Current oncology (Toronto, Ont.) · 2025Article
- The relationship between pan-immune inflammation value and different stages of diabetic retinopathy in patients with type 2 diabetes mellitus: a prospective cross-sectional study.BMC endocrine disorders · 2025Article
- Prognostic impact of pan-immune inflammation value in small-cell lung cancer treated with chemoradiotherapy and prophylactic cranial irradiation.Biomolecules & biomedicine · 2025Article
- Correlation between pan immune inflammation value and testosterone deficiency risk increase.Scientific reports · 2025Article
- Prognostic value of preoperative modified Glasgow prognostic score in predicting overall survival in breast cancer patients: A retrospective cohort study.Oncology letters · 2025Article
- Prognostic Importance of Panimmune-Inflammation Value and PILE Scores in Non-Metastatic Luminal A Breast Cancer.Breast care (Basel, Switzerland) · 2025Article
- Pan-Immune-Inflammation Value Predicts 3-Month Functional Outcomes in Patients With Acute Ischemic Stroke Treated With Mechanical Thrombectomy.Brain and behavior · 2025Article
- Association between pan-immune inflammatory value and all-cause mortality in critically ill patients with ischemic stroke: a retrospective analysis of the MIMIC-IV database (2008-2022).Frontiers in neurology · 2025Article
- Associations between systemic inflammatory indices and the risk of renal function decline in patients with type 2 diabetes mellitus: a retrospective cohort study.Frontiers in endocrinology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The newly discovered pan-immune-inflammation value (PIV) has been illustrated to have good prognostic value for cancer patient prognosis. However, the prognostic usefulness of PIV in breast cancer patients is unknown. As a result, to aid the clinic in providing a distinctive and trustworthy biomarker to better assess breast cancer patient's prognosis, we conducted this meta-analysis to investigate the relationship between PIV and the survival of breast cancer patients. Methods: We conducted a systematic search of Pubmed, Embase, the Cochrane Library, and the CNKI databases to screen for eligible studies published up to April 2023. Outcomes included overall survival (OS), progression-free survival (PFS), and pathological complete response (pCR). The hazard ratio (HR) and the corresponding 95% confidence interval (CI) were used as the indicators. STATA 15.0 software was used to perform meta-analysis, sensitivity analysis, and publication bias analysis. Results: A total of eight articles, involving 2953 patients, met the inclusion criteria and were included in this meta-analysis. The results showed that patients with higher PIV levels had a significantly shorter OS (HR: 2.045, 95% CI: 1.355-3.086, Conclusions: PIV has a good prognostic value in breast cancer patients and is expected to be a prognostic biomarker for breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.